Cellarity turning network maps into programs for complex diseases with $123M series B

Flagship-founded single-cell analysis company Cellarity is using its $123 million series B round to advance seven preclinical programs across four complex disease areas, turning the corner from a scientific discovery shop to an integrated drug discovery company.

Founded in 2017, Cellarity Inc. emerged from stealth in 2019 with a $50 million investment from Flagship. Joining the firm in Cellarity’s series B round were funds and accounts managed by BlackRock, The Baupost Group and Banque Pictet on behalf of their clients, as well as eight other undisclosed investors. ...